Skip to main content

Hematologist joins podcast to highlight studies in clonal hematopoiesis of indeterminate potential

Catherine Coombs, MD

Catherine Coombs, MD, an Associate Professor in the Division of Hematology/Oncology at the University of California, Irvine, School of Medicine, highlights recent studies in clonal hematopoiesis of indeterminate potential (CHIP) presented at the 65th American Society of Hematology Annual Meeting & Exposition in the fourth episode of the second season of “The HemOnc Pulse.”

Dr. Coombs discussed research (abstract #937) on reversing the adverse effects of CHIP, particularly its association with atherosclerotic cardiovascular disease, using interventions such as eltanexor, a selective nuclear export inhibitor.

“My hope is that if this ever goes into human trials, CHIP has … to be well tolerated,” she said. “I don’t know a ton about the drug. I have seen selinexor dating back to phase I trials, and [it] certainly [is] not the most benign drug with respect to its toxicity. Nonetheless, this is a newer version of that drug. If they could find a way to make it a very well-tolerated drug, I think it could be interesting.”